AUS
NZ
UK
CA
USA
IND
Highlights
- Sonoma Pharmaceuticals (NASDAQ:SNOA) is set to release its latest earnings before the market opens on February 13th, with projections indicating an earnings per share (EPS) of ($0.80) and revenue of $4.39 million for the quarter.
- The company reported an EPS of ($0.59) in its previous earnings announcement, while demonstrating a negative return on equity of 59.58% and a negative net margin of 27.21%.
- With a market capitalization of $3.56 million, Sonoma Pharmaceuticals offers various HOCl-based products across multiple healthcare sectors globally, functioning in a competitive and dynamic marketplace.
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) is ready to unveil its financial performance for the quarter as the market anticipates their earnings announcement on February 13th. Analysts predict the company will report an earnings per share of ($0.80) alongside $4.39 million in revenue for this period. Such expectations follow the company's prior quarterly performance, during which it disclosed an earnings per share of ($0.59) on February 5th. This performance was marked by a negative return on equity of 59.58% and a net margin deficit of 27.21%.
Currently trading at $2.66, Sonoma Pharmaceuticals maintains a market capitalization of $3.56 million. The company's stock has experienced fluctuations, ranging from a low of $2.44 to a high of $9.37 over the past 52 weeks. Key stock metrics include a P/E ratio of -0.53 and a beta of 1.43, indicating both the risk and volatility associated with holding their stock. The fifty-day moving average of $2.69 and the two-hundred-day average of $2.37 provide insights into the company's recent trading performance.
Sonoma Pharmaceuticals: Product Portfolio and Market Reach
Known for pioneering stabilized hypochlorous acid (HOCl) product development, Sonoma Pharmaceuticals delivers a diverse array of healthcare solutions. Its offerings include Regenacyn, the scar gel available by prescription; Pediacyn, designed for pediatric dermatology and wound care for over-the-counter use; and Epicyn, an antimicrobial facial cleanser. Leveraging HOCl technology, it also distributes Levicyn, which can be employed to relieve various skin irritations such as lacerations, abrasions, and burns, along with Celacyn, targeted towards scar management, and SebuDerm, alleviating the symptoms associated with seborrhea and seborrheic dermatitis.
With its footprint extending beyond the United States to markets in Latin America, Europe, Asia, and more, Sonoma Pharmaceuticals has emphasized innovation and expansion in various sectors, from wound care to dermatological treatments and more. The company's strategic endeavors in these domains reveal a dedication to addressing healthcare needs through advanced formulation and global distribution.
